Journal of Antimicrobial Chemotherapy (2000) 46, 489-492
© 2000 The British Society for Antimicrobial Chemotherapy
Brief reports |
Ketolide ABT-773 is active against Toxoplasma gondii
a Research Institute, Palo Alto Medical Foundation, Ames Building, 795 El Camino Real, Palo Alto, CA; b Stanford University School of Medicine, Palo Alto, CA 94301; c Abbott Laboratories, Chicago, IL, USA
ABT-773 is active in vitro and in vivo against Toxoplasma gondii. It inhibited replication of RH strain tachyzoites in human foreskin fibroblasts. Mice infected intraperitoneally with tachyzoites and treated orally with 25, 50 or 100 mg/kg/day of ABT-773 for 10 days had 20% (P = 0.016), 50% (P = 0.003) and 100% (P = 0.001) survival, respectively. Remarkable and highly significant survival was also noted in mice infected orally with strain C56 cysts and treated with ABT-773. Thus, ABT-773 may be useful for therapy of human toxoplasmosis.
* Corresponding author. Tel: +1-650-853-6061; Fax: +1-650-329-9853.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. H. Edelstein, F. Higa, and M. A. C. Edelstein In Vitro Activity of ABT-773 against Legionella pneumophila, Its Pharmacokinetics in Guinea Pigs, and Its Use to Treat Guinea Pigs with L. pneumophila Pneumonia Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2685 - 2690. [Abstract] [Full Text] |
||||
![]() |
N. Schöler, K. Krause, O. Kayser, R. H. Müller, K. Borner, H. Hahn, and O. Liesenfeld Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1771 - 1779. [Abstract] [Full Text] |
||||
